Sensitivity of melphalan-resistant tumors to selenite in vivo

Paula B. Caffrey, Gerald D. Frenkel

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Previous studies have demonstrated that melphalan-resistant human ovarian tumor cells exhibit a higher degree of sensitivity to the cytotoxic effects of selenite in vitro than comparable drug-sensitive cells. We have now examined the sensitivity of drug-resistant tumors to selenite in vivo. A2780 human ovarian tumor cells, or their melphalan-resistant derivative (A2780ME) cells were injected subcutaneously into nude mice and the resulting tumors were found to be melphalan-sensitive and -resistant, respectively, in vivo. Treatment with selenite (2 mg/kg Se s.c.), which had no overt toxic effect on the animals, resulted in a significant decrease in the rate of growth of the melphalan-resistant tumors, but not on the rate of growth of the drug-sensitive tumors. Thus, melphalan-resistant ovarian tumors are also more sensitive to selenite treatment in vivo.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalCancer Letters
Issue number2
StatePublished - Dec 23 1997

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • Drug resistance
  • In vivo
  • Melphalan
  • Ovarian tumors
  • Selenite


Dive into the research topics of 'Sensitivity of melphalan-resistant tumors to selenite in vivo'. Together they form a unique fingerprint.

Cite this